Wuhan Yanzhe Technology

Wuhan Yanzhe Technology is a clinical-stage biopharmaceutical company headquartered in Wuhan, China, specializing in the development of next-generation small molecule drugs for oncology. The company's primary focus is on addressing unmet medical needs in cancer treatment through the optimization of kinase inhibitors and other targeted therapies. Its lead program, YZ-101, is a potent and selective CDK4/6 inhibitor designed to offer improved safety and efficacy profiles compared to first-generation inhibitors. Wuhan Yanzhe Technology operates out of the Wuhan National Bio-industry Base (Optics Valley), utilizing a lean R&D model to advance its pipeline from discovery to clinical proof-of-concept. The company leverages deep expertise in medicinal chemistry to target well-validated biological pathways with differentiated molecular entities.